Committee for Medicinal Products for Human Use (CHMP) issues positive recommendation for approval of insulin lispro (Liumjev) for treatment of diabetes mellitus in adults

Liumjev will be available as solution for injection (100 units/ml and 200 units/ml) and contains insulin lispro, a fast-acting insulin analogue, which is absorbed more rapidly by the body and can therefore act faster than injected human insulin.


European Medicines Agency